Site-specific integration of large genes in human primary stem cells remains a significant challenge in gene therapy, particularly for treating multiallelic diseases. Gene editing efficiency in primary stem cells is heavily influenced by the delivery strategy, which often faces issues with programmability, efficiency, and specificity. Here, we developed a dual-viral delivery system, targeted integration via virus-like particles and integrase-deficient lentivirus (TIVID). This system combines virus-like Cas9 edit particles for delivering Cas9/sgRNA ribonucleoprotein complexes and integrase-deficient lentiviral vectors for delivering HDR donor templates. The TIVID system achieves a knock-in efficiency of 65% ± 5% in human induced pluripotent stem cells (iPSCs). In erythroid progenitor HUDEP2 cells, TIVID mediates precise integration of a 7.1 kb HBB-GFP cassette (from cut site to cut site) at the AAVS1 locus with 20% efficiency and stable expression. Crucially, we demonstrate that TIVID overcomes stringent packaging constraints to deliver an approximately 6 kb full-length HBB therapeutic cassette into primary human CD34+ hematopoietic stem and progenitor cells. This platform achieved 5–10% targeted integration efficiency and preserved robust lineage-specific differentiation capacity, demonstrating its potential for treating β-thalassemia and other multiallelic disorders. In head-to-head comparisons, TIVID outperformed lentivirus-derived nanoparticles (∼50% vs. <10% at AAVS1 in K562 with M3814) and plasmid-based eePASSIGE in iPSCs (∼20% vs. ∼1.5%). Compared with traditional electroporation delivery, TIVID offers lower early cytotoxicity, promotes predominantly mono-allelic integration, and exhibits enhanced compatibility with primary stem cells. By decoupling nuclease and donor delivery, TIVID circumvents the payload constraints of single-vector systems and the toxicity of physical transfection, providing a robust ex vivo engineering platform for complex gene replacement therapies.
JinekM, ChylinskiK, FonfaraI, et al.A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science2012;337(6096):816–821.
2.
AutonA, BrooksLD, DurbinRM, et al.A global reference for human genetic variation. Nature2015;526:68–74.
3.
WeischenfeldtJ, SymmonsO, SpitzF, et al.Phenotypic impact of genomic structural variation: Insights from and for human disease. Nat Rev Genet2013;14(2):125–138.
4.
CastellaM, PujolR, CallénE, et al.Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood2011;117(14):3759–3769.
5.
MahdiehN, RabbaniB. Beta thalassemia in 31,734 cases with HBB gene mutations: Pathogenic and structural analysis of the common mutations; Iran as the crossroads of the Middle East. Blood Rev2016;30(6):493–508.
6.
LiuZ, ZhangY, ZhuM, et al.Identification of candidate nonsense mutations of FVIII for ribosomal readthrough therapy. Haematologica2019;104(12):e573–e576.
7.
LedfordH. World first: Ultra-powerful CRISPR treatment trialled in a person. Nature2025;641(8065):108-3.
8.
MusunuruK, GrandinetteSA, WangX, et al.Patient-specific in vivo gene editing to treat a rare genetic disease. N Engl J Med2025;392(22):2235–2243.
9.
ChavezM, RaneDA, ChenX, et al.Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus. Nat Biomed Eng2023;7(5):661–671.
10.
SelvarajS, FeistWN, VielS, et al.High-efficiency transgene integration by homology-directed repair in human primary cells using DNA-PKcs inhibition. Nat Biotechnol2024;42(5):731–744.
11.
ZhangJ-P, LiX-L, LiG-H, et al.Efficient precise knockin with a double cut HDR donor after CRISPR/Cas9-mediated double-stranded DNA cleavage. Genome Biol2017;18(1):35.
12.
AnzaloneAV, GaoXD, PodrackyCJ, et al.Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat Biotechnol2022;40(5):731–740.
13.
KlompeSE, VoPLH, Halpin-HealyTS, et al.Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration. Nature2019;571(7764):219–225.
14.
LampeGD, KingRT, Halpin-HealyTS, et al.Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases. Nat Biotechnol2024;42(1):87–98.
15.
PandeyS, GaoXD, KrasnowNA, et al.Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing. Nat Biomed Eng2025;9(1):22–39.
16.
StreckerJ, LadhaA, GardnerZ, et al.RNA-guided DNA insertion with CRISPR-associated transposases. Science2019;365(6448):48–53.
17.
TouCJ, OrrB, KleinstiverBP. Precise cut-and-paste DNA insertion using engineered type V-K CRISPR-associated transposases. Nat Biotechnol2023;41(7):968–979.
18.
WitteIP, LampeGD, EitzingerS, et al.Programmable gene insertion in human cells with a laboratory-evolved CRISPR-associated transposase. Science2025;388(6748):eadt5199.
19.
XieK, StarzykJ, MajumdarI, et al.Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration. Nat Biotechnol2025;43(11):1821–1832.
20.
YarnallMTN, IoannidiEI, Schmitt-UlmsC, et al.Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat Biotechnol2023;41(4):500–512.
21.
CornuTI, MussolinoC, CathomenT. Refining strategies to translate genome editing to the clinic. Nat Med2017;23(4):415–423.
22.
BakRO, DeverDP, PorteusMH. CRISPR/Cas9 genome editing in human hematopoietic stem cells. Nat Protoc2018;13(2):358–376.
23.
MartinRM, IkedaK, CromerMK, et al.Highly efficient and marker-free genome editing of human pluripotent stem cells by CRISPR-Cas9 RNP and AAV6 donor-mediated homologous recombination. Cell Stem Cell2019;24(5):821–828 e825.
24.
FerrariS, JacobA, BerettaS, et al.Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking. Nat Biotechnol2020;38(11):1298–1308.
PavaniG, LaurentM, FabianoA, et al.Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins. Nat Commun2020;11(1):3778.
27.
SchiroliG, ContiA, FerrariS, et al.Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell2019;24(4):551–565 e558.
28.
SuchyFP, KariganeD, NakauchiY, et al.Genome engineering with Cas9 and AAV repair templates generates frequent concatemeric insertions of viral vectors. Nat Biotechnol2025;43(2):204–213.
29.
SaeedMQ, DufourN, BartholmaeC, et al.Comparison between several integrase-defective lentiviral vectors reveals increased integration of an HIV vector bearing a D167H mutant. Mol Ther Nucleic Acids2014;3:e213.
30.
NguyenDN, RothTL, LiPJ, et al.Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat Biotechnol2020;38(1):44–49.
31.
PorteusMH. A new class of medicines through DNA editing. N Engl J Med2019;380(10):947–959.
32.
RothTL, Puig-SausC, YuR, et al.Reprogramming human T cell function and specificity with non-viral genome targeting. Nature2018;559(7714):405–409.
33.
AnM, RaguramA, DuSW, et al.Engineered virus-like particles for transient delivery of prime editor ribonucleoprotein complexes in vivo. Nat Biotechnol2024;42(10):1526–1537.
34.
BanskotaS, RaguramA, SuhS, et al.Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins. Cell2022;185(2):250–265 e216.
35.
HaldrupJ, AndersenS, LabialARL, et al.Engineered lentivirus-derived nanoparticles (LVNPs) for delivery of CRISPR/Cas ribonucleoprotein complexes supporting base editing, prime editing and in vivo gene modification. Nucleic Acids Res2023;51(18):10059–10074.
36.
HamiltonJR, ChenE, PerezBS, et al.In vivo human T cell engineering with enveloped delivery vehicles. Nat Biotechnol2024;42(11):1684–1692.
37.
LingS, YangS, HuX, et al.Lentiviral delivery of co-packaged Cas9 mRNA and a Vegfa-targeting guide RNA prevents wet age-related macular degeneration in mice. Nat Biomed Eng2021;5(2):144–156.
38.
AndersenS, WolffJH, SkovTW, et al.Gene editing in hematopoietic stem cells by co-delivery of Cas9/sgRNA ribonucleoprotein and templates for homology-directed repair in ‘all-in-one’ lentivirus-derived nanoparticles. Nucleic Acids Res2025;53(15):gkaf767.
39.
FuJ, FuY-W, ZhaoJ-J, et al.Improved and flexible HDR editing by targeting introns in iPSCs. Stem Cell Rev Rep2022;18(5):1822–1833.
40.
FuY-W, DaiX-Y, WangW-T, et al.Dynamics and competition of CRISPR-Cas9 ribonucleoproteins and AAV donor-mediated NHEJ, MMEJ and HDR editing. Nucleic Acids Res2021;49(2):969–985.
41.
RiesenbergS, ChintalapatiM, MacakD, et al.Simultaneous precise editing of multiple genes in human cells. Nucleic Acids Res2019;47(19):e116.
42.
LiX-L, LiG-H, FuJ, et al.Highly efficient genome editing via CRISPR-Cas9 in human pluripotent stem cells is achieved by transient BCL-XL overexpression. Nucleic Acids Res2018;46(19):10195–10215.
43.
LabunK, MontagueTG, GagnonJA, et al.CHOPCHOP v2: A web tool for the next generation of CRISPR genome engineering. Nucleic Acids Res2016;44(W1):W272–W276.
44.
ChenW, WangC, YangZ-X, et al.Reprogramming of human peripheral blood mononuclear cells into induced mesenchymal stromal cells using non-integrating vectors. Commun Biol2023;6(1):393.
45.
KuritaR, SudaN, SudoK, et al.Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells. PLoS One2013;8(3):e59890.
46.
ChenPJ, HussmannJA, YanJ, et al.Enhanced prime editing systems by manipulating cellular determinants of editing outcomes. Cell2021;184(22):5635–5652 e5629.
47.
CromerMK, VaidyanathanS, RyanDE, et al.Global transcriptional response to CRISPR/Cas9-AAV6-based genome editing in CD34(+) hematopoietic stem and progenitor cells. Mol Ther2018;26(10):2431–2442.
48.
DeverDP, BakRO, ReinischA, et al.CRISPR/Cas9 beta-globin gene targeting in human haematopoietic stem cells. Nature2016;539(7629):384–389.
49.
ChenB, GilbertLA, CiminiBA, et al.Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell2013;155(7):1479–1491.
50.
ZhaoJJ, TianSN, PengZY, et al.Biomembrane-inspired lipid nanoparticles enhance CRISPR-Cas9 editing for hemophilia A. J Control Release2025;386:114141.
51.
HockemeyerD, SoldnerF, BeardC, et al.Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol2009;27(9):851–857.
52.
LombardoA, CesanaD, GenoveseP, et al.Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods2011;8(10):861–869.
53.
SadelainM, PapapetrouEP, BushmanFD. Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer2011;12(1):51–58.
54.
MajiB, GangopadhyaySA, LeeM, et al.A high-throughput platform to identify small-molecule inhibitors of CRISPR-Cas9. Cell2019;177(4):1067–1079 e1019.
55.
AlerasoolN, SegalD, LeeH, et al.An efficient KRAB domain for CRISPRi applications in human cells. Nat Methods2020;17(11):1093–1096.
56.
ReplogleJM, BonnarJL, PogsonAN, et al.Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors. Elife2022;11:e81856.
57.
GaoZ-Y, YangZ-X, DengD-H, et al.G2B: An optimized lentiviral vector with enhanced titer and beta-globin expression for improved beta-thalassemia gene therapy. Blood Sci2025;7(4):e00253.
58.
LocatelliF, ThompsonAA, KwiatkowskiJL, et al.Betibeglogene autotemcel gene therapy for non-beta(0)/beta(0) genotype beta-thalassemia. N Engl J Med2022;386:415–427.
59.
FurukawaY, HamanoY, ShiraneS, et al.Advances in allogeneic cancer cell therapy and future perspectives on “Off-the-Shelf” T cell therapy using iPSC technology and gene editing. Cells2022;11(2):269.
60.
KadriN, AmuS, IacobaeusE, et al.Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cell Mol Immunol2023;20(6):613–625.
61.
KholosyWM, VisscherM, OginkK, et al.Simple, fast and efficient iTOP-mediated delivery of CRISPR/Cas9 RNP in difficult-to-transduce human cells including primary T cells. J Biotechnol2021;338:71–80.
62.
ZongJ, LiYR. iPSC technology revolutionizes CAR-T cell therapy for cancer treatment. Bioengineering (Basel)2025;12(1):60.
63.
LinX, SunY, DongX, et al.IPSC-derived CAR-NK cells for cancer immunotherapy. Biomed Pharmacother2023;165:115123.
64.
NybergWA, BernardP-L, NgoW, et al.In vivo site-specific engineering to reprogram T cells. Nature2026;652(8110):712–721.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
